Abstract
BackgroundImmunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer...
Highlights
IntroductionImmunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC)
Immunotherapy targeting the checkpoint PD1 or PDL1 has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC)
T cell activation induced by checkpoint inhibition may dramatically improve tumor response to radiation
Summary
Immunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC) The use of such therapies has been introduced into the treatment of other malignancies, including head and neck cancer. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction of PD-1 with its ligands, PD-L1 and PD-L2 It is FDA approved for the treatment of melanoma and NSCLC and was recently granted accelerated approval for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients with disease progression on or after platinum-containing chemotherapy [1]. The patient subsequently developed regional progression and was treated with weekly methotrexate and cetuximab and she achieved stable disease (SD) for 6 months Later, she progressed locally and was enrolled into a trial utilizing single agent pembrolizumab. She had SD for 6 cycles (Fig. 1), and
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
